First News

Advantages of companion diagnostics, the growing need for targeted therapy, the rising importance of personalized medicine, the increasing global incidence of cancer, and the ever-increasing application areas of companion diagnostics are driving the growth of the global companion diagnostics industry. The increasing demand for next-generation sequencing, the growing significance of companion diagnostics in drug development, and the rising number of clinical trials are the major factors driving the growth of this market. [333 Pages Report] The companion diagnostics market is expected to reach USD 6.8 billion by 2025 from USD 3.7 billion in 2020, at a CAGR of 12.9% during the forecast period of 2020 to 2025. Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681 COVID-19 Impact on Companion Diagnostics Market The companion diagnostics market includes major Tier I and II companies like Roche Diagnostics, Agilent Technologies, Qiagen, Thermo Fisher, a...

According to the new market research report “ Companion Diagnostics Market   by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User (Pharma Companies, CRO), Region — Global Forecast to 2024 ”, published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW). The global companion diagnostic market is is projected to reach USD 7.3 billion by 2024 from USD 3.5 billion in 2019, at a CAGR of 15.7%. The growth of the market can be attributed to increasing lung cancer cases, growing number of genetic testing, rising need for personalized medicines, and regulatory guidelines that support the companion diagnostics market. However, uncertainty in the reimbursement scenario in different countries is expected to hinder market growth. Don’t miss ...

The growth of the  companion diagnostics market  is tied primarily to the advantages of companion diagnostics, the growing need for targeted therapy, the increasing importance of personalized medicine, the rising global incidence of cancer, and the ever-increasing application areas of companion diagnostics. What the Market Looks Like? Predicted to grow at a CAGR of 15.7% during the forecast period, the global Companion Diagnostics Market is estimated to reach USD 7.3 billion by 2024 by the end of 2024. In 2019, North America held the largest market share, followed by Europe. Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681 The assays, kits, & reagents segment is expected to account for the largest share of the companion diagnostics market in 2019. This is attributed to the availability of a wide range of assays, kits, & reagents in companion diagnostics, increasing the use of assays & kits in different therapeutic area...

A companion diagnostic assay is an in vitro diagnostic device (IVD) that is used to identify whether a patient with certain diseases could be benefitted by a particular drug through the biomarker assessment. The key factors driving the growth of this market include the increasing lung cancer cases, growing number of genetic testing, rising need for personalized medicines, and regulatory guidelines that support the  companion diagnostics market . The  global companion diagnostics market  is projected to reach USD 7.3 billion by 2024 from USD 3.5 billion in 2019, at a  CAGR  of 15.7%. Market Dynamics – Drivers Advantages of Companion Diagnostics Growing Need for Targeted therapy Growing Importance of Personalized Medicine Increasing Global Incidence of Cancer Growing Application Areas of Companion Diagnostics Polymerase chain reaction (PCR) segment to account for the largest share of the companion diagnostics market, by technology, in 2019 The extractables/leachab...

A companion diagnostic assay is an in vitro diagnostic device (IVD) that is used to identify whether a patient with certain diseases could be benefitted by a particular drug through the biomarker assessment. The key factors driving the growth of this market include the increasing lung cancer cases, growing number of genetic testing, rising need for personalized medicines, and regulatory guidelines that support the companion diagnostics market. What is growth in  Companion Diagnostics  Market ? The  global companion diagnostics market  is expected to reach $6.51 billion by 2022 from $2.17 billion in 2016, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development. Rising adoption of companion diagnostics assay kits & reagents in maj...

A companion diagnostic assay is an in vitro diagnostic device (IVD) that is used to identify whether a patient with certain diseases could be benefitted by a particular drug through the biomarker assessment. The key factors driving the growth of this market include the increasing lung cancer cases, growing number of genetic testing, rising need for personalized medicines, and regulatory guidelines that support the  companion diagnostics market . The base year considered for the study is 2016, and the forecast has been provided for the period between 2017 and 2022. The global companion diagnostics market is expected to reach USD 6.51 billion by 2022 from USD 2.17 billion in 2016, at a CAGR of 20.1%. Market Dynamics + Drivers + Improvements in regulatory guidelines + Growing need for targeted therapies + Rising cancer incidence worldwide + Increasing collaborations and partnerships for companion diagnostics test development Increasing collaborations and partnerships for companion dia...

According to the new market research report  “ Companion Diagnostics Market  by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022" , published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW). Don’t miss out on business opportunities in Companion Diagnostics Market.  Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=155571681 A companion diagnostic assay is an in vitro diagnostic device (IVD) that is used to identify whether a patient with certain disease could be benefitted by a particular drug through the biomarker assessment. The report analyzes the companion ...

According to the new market research report " Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022 ", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW). The growth of the market can be attributed to increasing lung cancer cases, growing number of genetic testing, rising need for personalized medicines, and regulatory guidelines that support the  companion diagnostics market . However, uncertainty in the reimbursement scenario in different countries is expected to hinder market growth. Don’t miss out on business opportunities in Companion Diagnostics Market.  Speak to our analyst and gain crucial industry insights that will help...